From the Research
The Sampras trial is not directly mentioned in the provided evidence, however, the SAMMPRIS trial is discussed in several studies, which may be relevant to the question. The SAMMPRIS trial was a significant clinical study that evaluated the effectiveness of aggressive medical management with or without stenting in high-risk patients with intracranial artery stenosis 1. The trial found that aggressive medical management was more effective than stenting with the Wingspan stent in reducing the risk of stroke and death in these patients. Specifically, the study found that the cumulative probability of primary endpoints was smaller in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0.0252) 1.
- Key findings of the SAMMPRIS trial include:
- Aggressive medical management was more effective than stenting with the Wingspan stent in reducing the risk of stroke and death in high-risk patients with intracranial artery stenosis 1.
- The cumulative probability of primary endpoints was smaller in the medical group versus the PTAS group (p=0.0252) 1.
- The occurrence of adverse events, including any stroke and major hemorrhage, was higher in the PTAS group than in the medical group 1.
- The SAMMPRIS trial helps guide clinical decision-making by suggesting that aggressive medical management is a more effective treatment option than stenting with the Wingspan stent for high-risk patients with intracranial artery stenosis, and that the benefits of medical management must be weighed against the potential risks of stenting, including stroke and major hemorrhage 1. The most recent and highest quality study on this topic is the 2014 study published in The Lancet, which provides the most relevant and reliable evidence for guiding clinical decision-making 1.